Antiandrogen Therapy

Phase 3Small molecule

Antiandrogen Therapy is one of 101 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaNot yet recruiting

Prostate CarcinomaRecruiting

Prostate CancerCompleted

Biochemically Recurrent Prostate CarcinomaActive, not recruiting

Stage IV Prostate Adenocarcinoma AJCC V7Active, not recruiting

Castration-Sensitive Prostate CarcinomaActive, not recruiting

Prostate AdenocarcinomaPhase 3

Not yet recruiting

Prostate CarcinomaPhase 2

Recruiting

Prostate CancerPhase 3

Completed

Biochemically Recurrent Prostate CarcinomaPhase 3

Active, not recruiting

Stage IV Prostate Adenocarcinoma AJCC V7Phase 2

Active, not recruiting

Castration-Sensitive Prostate CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Phase 3

14 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

9 3

Triptorelin Embonate

Ipsen

Phase 3

3 4

Lhrha

Johnson & Johnson

Phase 3

2 5

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 6

Fuzuloparib

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 7

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

2 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Stage IV Prostate Adenocarcinoma AJCC V7

NCT03456843

Q4 2027

Phase 2Active, not recruiting

Prostate Cancer

NCT03541850

Q1 2028

Phase 2Recruiting

Castration-Sensitive Prostate Carcinoma

NCT06244004

Q2 2028

Phase 2Recruiting

Prostate Carcinoma

NCT07202247

Phase 2Recruiting

Prostate Carcinoma

NCT04947254

Clinical

Trials by Indication[1]

Prostate Cancer9 trials

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Terminated·TThomas Jefferson University·Phase 2·NCT05676463·6 enrolled

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT03541850·92 enrolled

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Unknown status·CCancer Research UK·N/A·NCT00967954·120 enrolled

Show 6 more trials

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT02472275·8 enrolled

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Terminated·UUniversity of Washington·Phase 2·NCT03649841·10 enrolled

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01409200·73 enrolled

Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT00685646·227 enrolled

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

Terminated·UUniversity of Utah·Phase 2·NCT03827473·1 enrolled

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 3·NCT00110162·2,000 enrolled

Metastatic Prostate Cancer2 trials

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

Completed·UUniversity of Washington··NCT00392938·11 enrolled

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

Completed·UUNICANCER·Phase 3·NCT00104715·385 enrolled

Prostate Adenocarcinoma2 trials

A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07914855·24 enrolled

Phase 1 Dose-Escalation and Expansion Study of IL-18 Armored STEAP1 CAR T in Participants With mCRPC

Not yet recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT07803653·20 enrolled

Castration-Sensitive Prostate Carcinoma2 trials

A Randomized Open Label Phase II Trial of FDG-PET-Guided Metastasis Directed Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer: PRTY Trial: PET- Guided Radiotherapy Consolidation

Recruiting·NNorthwestern University·Phase 2·NCT06244004·125 enrolled

Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT04267887·7 enrolled

Prostate Carcinoma2 trials

A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT)

Recruiting·CCity of Hope Medical Center·Phase 2·NCT07202247·60 enrolled

Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04947254·200 enrolled

3 more indications

High Risk1 trial

Post-operative or Early Salvage XRT and ADT for High Risk PCa

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00949962·87 enrolled

Biochemically Recurrent Prostate Carcinoma1 trial

Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy

Active, not recruiting·MMayo Clinic·Phase 3·NCT06205316·118 enrolled

Stage IV Prostate Adenocarcinoma AJCC v71 trial

SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer

Active, not recruiting·YYale University·Phase 2·NCT03456843·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Antiandrogen Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiandrogen Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiandrogen Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Washington

Antiandrogen Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Prostate Cancer9 trials

Metastatic Prostate Cancer2 trials

Prostate Adenocarcinoma2 trials

Castration-Sensitive Prostate Carcinoma2 trials

Prostate Carcinoma2 trials

High Risk1 trial

Biochemically Recurrent Prostate Carcinoma1 trial

Stage IV Prostate Adenocarcinoma AJCC v71 trial

References

Drug Info

Quick Facts

Related News